Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy (Q71834117)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference

M Nangaku

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

J Pippin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

C A Richardson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

M Schulze

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

B A Young

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

C E Alpers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

K L Gordon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

R J Johnson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

W G Couser

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

language of work or name

English

0 references

publication date

1 December 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

2054-2062

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

Clinical Membranous Nephropathy

21 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

NIH conference. Membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Treatment of idiopathic membranous glomerulopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Controlled trial of cyclophosphamide in idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Pathogenesis of membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

C5b-9 increases albumin permeability of isolated glomeruli in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Treatment of systemic vasculitis with pooled intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Manipulating the Immune System with Immune Globulin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

HUS and TTP: variable expression of a single entity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

A new role for complement in experimental membranous nephropathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Theβ-Cys-γ-Glu thiolester bond in human C3, C4, andα 2-macroglobulin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Regulation of complement

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

The complement membrane attack complex stimulates the prostanoid production of cultured glomerular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.529

7 January 2021

Identifiers

DOI

10.1038/KI.1996.529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8943490%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference